During cancer progression, majority of cancer cells were putatively clones of minority by MET exon 14 clones, with diminished clones with FGF-FGFR or WNT, ERBB2, MAPK pathways, which may lead less FGFR-Activated or Bypass-Activated subtype in more advanced disease stages. This evidence concerns the gene ERBB2 and cancer.